Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence?

Long-term disease control is achieved in 80–90% of patients with acute lymphoblastic leukemia of B origin (B-ALL). About half of adult and 10% of pediatric patients develop refractory or relapsed disease, whereas survival after relapse accounts about 10% in adults and 30–50% in children. Allogeneic...

Descripción completa

Detalles Bibliográficos
Autores principales: Komitopoulou, Anna, Baltadakis, I., Peristeri, I., Goussetis, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358786/
https://www.ncbi.nlm.nih.gov/pubmed/35950202
http://dx.doi.org/10.1007/s44228-022-00006-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358786/
https://www.ncbi.nlm.nih.gov/pubmed/35950202
http://dx.doi.org/10.1007/s44228-022-00006-6

Ejemplares similares